Catalyst OrthoScience CEO leaves to lead Raumedic Inc.

Raumedic Inc. President and CEO Brian Hutchison [Photo courtesy of Raumedic]

Brian Hutchison has taken over as president and CEO of Raumedic Inc. after stepping down from the same roles at Catalyst OrthoScience last month.

Hutchison joined Naples, Florida-based Catalyst as executive chairman and CEO in 2018. He has been replaced as CEO of Catalyst by Carl O’Connell, but remains a “significant investor” in the upper extremity orthopedics device maker, the company said.

“We thank Brian for the work he has done to build this company to where it is today,” Catalyst said in a news release.

The most recent Raumedic Inc. CEO, Stefan Seuferling, will maintan his responsibility for the Helmbrechts, Germany-based medical device component developer and manufacturer’s global business operations as CEO of Raumedic AG and chair of Raumedic Inc., the company’s U.S. operations.…

Read more
  • 0

How medtech fared in the first waves of the pandemic

[Photo by Martin Sanchez on Unsplash]

Medtech industry revenue, research spending and employment declined in the first year of the COVID-19 pandemic, according to a Medical Design & Outsourcing analysis of financial data.

Total sales, R&D spending and employment for the world’s largest medical device companies declined in 2020 and early 2021, according to a Medical Design & Outsourcing analysis tallying the ongoing pandemic’s initial toll on the industry.

To compare performance before and during the pandemic, MDO used the financial data that we’ve historically gathered to rank our Big 100 companies in the last three years. The majority of these companies reported full-year results for 2020; others operate on a fiscal year and reported annual results in the first half of 2021.

Some companies are not in this year’s Big 100 but were included in the analysis because they were ranked in pre…

Read more
  • 0

RTI Surgical, Exactech form partnership to develop biologic bone substitutes

The FDA-cleared Optecure demineralized bone matrix [Image courtesy of RTI Surgical]

RTI Surgical announced a long-term agreement with Exactech for the development and supply of biologic bone substitutes.

The deal, announced today, includes RTI Surgical acquiring Exactech’s FDA-cleared Optecure demineralized bone matrix, used as a bone graft extender in the spine, pelvis, and extremities. RTI Surgical officials think Optecure will complement their portfolio of bone graft substitutes. RTI Surgical offers a portfolio of tissue-based, synthetic and metal implants to OEM customers.

Get the full story on our sister site MassDevice. 

Read more
  • 0